.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after an average follow-up of 11 months, clients along with metastatic intestinal tumors who obtained biomarker-matched therapies based on flowing cyst DNA profiling showed a more significant scientific benefit than those receiving incomparable treatment.